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ABSTRACT
Objective.  Neuromuscular efficiency 
(NME) is impaired in fibromyalgia (FM). 
Hyperbaric oxygen therapy (HBOT) is 
a medical treatment using 100% of oxy-
gen through an oxygen mask. HBOT in 
FM induces changes in cortical excita-
bility and a secondary reduction in pain 
and muscle fatigue. However, there are 
still no direct data indicating changes 
in muscle fatigue. The aim of this study 
was to assess whether the reduction in 
muscle fatigue so far attributed to a cen-
tral effect of HBOT can be directly de-
tected by means of non-invasive sEMG 
as a change in NME. 
Methods. The study was an observa-
tional longitudinal study on changes in 
NME induced by 20 sessions of HBOT 
at 2.4 atmosphere, in 22 patients with 
FM (3M; 19F) (age 49.8±9.5; height 
164.7±7.5; weight 63.8±12.7). sEMG 
was recorded in single differential 
configuration from the biceps brachii 
muscle during the 30-second fatigu-
ing contractions using linear arrays of 
eight adhesive electrodes. 
Results. Evaluations made before 
and immediately after the first session 
showed that maximal strength did not 
change (T0 49±20 N, T1 49±19 N, 
p=0.792), thus suggesting that HBOT 
did not induce muscle fatigue or po-
tentiation. After 20 sessions of HBOT, 
NME increased from 1.6±1.1 to 2.1±0.8 
(p=0.050), whereas maximal strength, 
EMG amplitude and muscle fibre CV 
did not change. 
Conclusion. HBOT did not improve 
muscle strength or change muscle fibre 
content, but improved the ability of the 
central motor command to generate 
the same effort (MVC) with fewer re-
cruited fibres. Our sEMG findings un-
derlined a modified central mechanism 
related to fibre type recruitment order, 
thus suggesting that muscle fatigue is 
not primarily a muscular problem, as 
also demonstrated by other authors 
with different methods. 
Introduction
Although its aetiology and efficacious 
treatment are still unclear, FM is a ma-
jor problem for all National Health Ser-
vices as many epidemiological studies 
have shown that affects a large number 
of people all over the world. A recent 
review of its prevalence in Europe has 
found that it affects 2.3% of the popula-
tion as a whole and up to 3.9% of fe-
males, and the trend is similar in North 
America (1.9%, 2.9% of females), 
South America (1.12%, 2.45% of fe-
males), and Asia (1.64%, 3.24% of fe-
males) (1).
The main somatic symptoms of fibro-
myalgia are diffuse musculoskeletal 
pain, stiffness and fatigue, all of which 
are related to the muscle system and 
its functioning. Various attempts have 
been made to find specific alterations in 
muscle fibres using light microscopy, 
histochemistry, electron microscopy, 
and ultrastructural techniques, and the 
published results agree in suggesting 
local muscle hypoxia as a possible 
cause of the development of both spe-
cific and non-specific biopsy findings 
(for a short review see ref. 2).
Neuromuscular efficiency has been 
studied in conditions such as chronic 
heart failure (3) or hypoxia exposure 
(4) using multi-channel surface EMG 
(sEMG). Neuromuscular efficiency can 
be defined as the ability of the nervous 
system to recruit muscles and muscle 
fibres appropriately in order to produce 
a given effect, which is impaired in pa-
tients with fibromyalgia (5), thus rais-
ing the question as to whether fatigue is 
more centrally mediated than a clinical 
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epiphenomenon of local muscle hypoxia.
The complexity of the syndrome is also 
reflected by the fact that pharmacologi-
cal (6), non-pharmacological (7) and 
cognitive behavioural treatments (8) do 
not seem to be predictably efficacious. 
Hyperbaric oxygen therapy (HBOT) 
is a medical treatment that enhances 
the body’s natural healing process by 
means of the inhalation of 100% oxy-
gen through an oxygen mask in which 
atmospheric pressure is increased and 
controlled. It has been used for a wide 
variety of conditions usually as part of 
planned overall medical care, and has 
led to promising results in the treat-
ment of a number of painful orthopedic 
and rheumatological conditions (9), 
headache, complex regional pain syn-
drome, and FM (10, 11). 
HOBT was proposed for FM on the hy-
pothesis that it could act centrally by 
inducing changes in cortical excitability 
(12), on the basis of single-photon emis-
sion computed tomography (SPECT) 
findings that FM patients show abnor-
mally high levels of activity in the so-
matosensory cortex, but reduced ac-
tivity in the frontal, cingulate, medial 
temporal, and cerebellar cortices (13). 
Eftari et al. showed that HBOT normal-
ised cortical excitability in a group of 
FM patients, and inferred a secondary 
reduction in pain and muscle fatigue on 
the grounds that the change temporally 
correlated with a clinical improvement 
on symptoms (12). However, there are 
still no direct data indicating changes in 
muscle fatigue. 
The primary aim of this study was to 
assess whether the reduction in muscle 
fatigue so far attributed to a central ef-
fect of HOBT can be directly detected 
by means of non-invasive sEMG of the 
biceps brachii muscle as a change in 
neuromuscular efficiency before and 
after treatments repeated over time in 
a group of patients with fibromyalgia. 
Methods
Patients
Twelve of an initially unselected group 
of 40 female patients with a confirmed 
diagnosis of fibromyalgia made by 
two experts (SP, FA) on the basis of 
the 1990 and 2010 American College 
of Rheumatology (ACR) criteria at the 
Department of Rheumatology, Univer-
sity Hospital Luigi Sacco, Milan, did 
not consent to participate in the study 
mainly because the length of the pro-
tocol and logistical problems (distance 
from the hospital). 
Patients with 1) inflammatory causes 
of pain; or muscle pain caused by con-
ditions such as vitamin D deficiency 
2) alcohol/drug abuse or dependence; 
3) significant difficulty in maintaining 
attention or understanding clinimetric 
evaluation instructions; 4) any clinical 
condition that may interfere with the 
assessment; 5) pregnant women or po-
tentially childbearing women not using 
an adequate method of birth control; 
and 6) any of the following medical 
conditions that preclude safe HBOT 
treatment: a) severe cognitive impair-
ment; b) current mood episodes, claus-
trophobia or seizure disorder; c) active 
or severe pulmonary disease, previous 
thoracic surgery or  pneumothorax; d) 
a history of severe heart disease; e) 
chronic or acute sinusitis/otitis media 
or major eardrum trauma; and f) a his-
tory of bleomycin-including chemo-
therapy or current chemotherapy were 
excluded from the study.
The remaining 28 were sent to the Hy-
perbaric Unit, Habilita Hospitals & Re-
search, Zingonia (Bergamo) to be as-
sessed by an expert for their eligibility 
for HBOT, and three were considered 
ineligible because of the presence of 
a clinical contraindication to the treat-
ment (14). 
Finally, of the 25 patients enrolled in 
the study, two dropped out because 
of the side effects of HBOT (15, 16), 
and one who was unwilling to continue 
the study because of unforeseen fam-
ily problems. The study was therefore 
completed by 22 patients (3 males and 
19 females) (mean age 50.6, min 28 
max 64 years; mean height 164.7, min 
164 max 175 cm; mean weight 66.9, 
mean 45 max 95 kg). All the patients 
received analgesic treatment (paraceta-
mol, tramadol) at stable doses before 
the enrollment in the study protocol. 
All the patients were in controlled re-
habilitation therapy, but no one was 
practicing heavy physical activity at 
the moment of enrollment. Ten patients 
were receiving duloxetine (mean dose 
30 mg/daily), five patients were treated 
with pregabalin (mean dose 75 mg/
daily), four patients were treated with 
amitriptyline (mean dose 50 mg/daily). 
The sEMG experimental protocol 
was carried out by two neurophysiol-
ogy technicians supervised by a trained 
neurologist (RC) who was blinded to 
the treatment. The data were analysed 
by AR,GB. All of the participants gave 
their written informed consent before 
taking part in the study, and the protocol 
was approved by the Scientific Techni-
cal Committee of Habilita (no. 6/2016).
EMG protocol
The subjects were familiarised with the 
sEMG device by being asked to make 
ten sub-maximal isometric contractions 
at 90° of elbow flexion (0°=full exten-
sion), and were then asked to make two 
maximal voluntary contraction (MVCs) 
separated by three minutes rest in or-
der to avoid any cumulative effects. 
If the MVCs differed from each other 
by more than 5%, a third MVC was 
required. Each attempted MVC lasted 
3–5 seconds, during which the sub-
jects were given strong verbal encour-
agement to maximise their effort, and 
received visual feedback generated by 
signal acquisition software. The great-
est MVC was used to calculate sub-
maximal loads.
Three minutes after the last MVC, the 
subjects were involved in two isometric 
contractions at respectively 30% and 
60% of the torque exerted during the 
MVC separated by a 5-minute interval. 
They received visual feedback about 
the actual torque exerted, and were 
instructed to maintain constant the tar-
get elbow flexion torque at 90° for 30 
seconds. They were also provided with 
standardised encouragement to keep 
the exerted torque as stable as possible.
EMG measurements
The myoelectrical signals were re-
corded in single differential configura-
tion from the long head of the biceps 
brachii muscle during the 30-second 
fatiguing contractions using linear ar-
rays of eight adhesive electrodes sepa-
rated by an inter-electrode distance of 
5 mm (OT Bioelettronica, Turin, Italy). 
Before the arrays were positioned, the 
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skin was slightly abraded with paste 
and cleaned with water in accordance 
with the skin preparation recommenda-
tions of the Surface Electromyography 
for the Non-invasive Assessment of 
Muscles (SENIAM) project (17). 
The optimal position and orientation 
of the array was sought on the basis of 
visual inspection of the sEMG signals. 
The sites showing the clear propagation 
of muscle fibre action potentials and the 
main innervation zones were identified 
using a dry linear array of 16 electrodes 
separated by an inter-electrode distance 
of 5 mm (OT Bioelettronica). The adhe-
sive electrode arrays were then placed 
parallel to the muscle fibres proximal to 
the innervation zone in which the unidi-
rectional propagation of the motor units 
(MU) action potentials was detected. In 
order to ensure correct electrode-skin 
contact, the electrode cavities were 
filled with 20-30 μl of conductive paste 
(Spes-Medica, Battipaglia, Italy), and 
the arrays were fixed using an extensible 
dressing (Fixomull®, Beiersdorf, D). 
The sEMG signals were amplified, sam-
pled at 2048 Hz, bandpass filtered (3 
dB bandwidth, 20-450 Hz, 12 dB/oct 
slope on each side), and converted to 
digital data using a 16-bit A/D converter 
(EMG-USB2+, OT Bioelettronica). 
Samples were visualised during acquisi-
tion, and then stored on a personal com-
puter using OT BioLab software (v. 1.8, 
OT Bioelettronica) for further analysis.
HBOT
Treatments were done using a hyperbaric 
chamber GAMMA, GALEAZZI S.p.A. 
n° 510/88, ISPESL n° SP 78-88. capac-
ity: 16 places (15 patients + 1 doctor).
Type of delivery of O2: the oxygen, 
stored in liquid form in a specific cryo-
genic tank, is gasified, normalised (am-
bient temperature and pressure 10 bar 
approx.) and supplied 100% pure to pa-
tients by means of individual breathing 
systems. The breathing system consists 
of a silicone oronasal mask with oxygen 
delivered  by a strigger system (average 
resistance 20–25 mm water column) 
which reduces the pressure at the en-
vironmental levels. Redundant systems 
of analysis of the percentage of oxygen 
present in the hyperbaric environment 
are present to ensure that the safety 
parameters are not exceeded (< 22%).
Delivery times: therapies are normally 
divided into 3 periods of oxygen breath-
ing of 20–25 minutes. Taking into ac-
count the times necessary for compres-
sion, decompression, oxygen respiration 
and pauses between the aforementioned 
periods, the indicative duration of an or-
dinary therapy was 91 minutes. 
O2 dispensation control: the mask is 
provided of a specific analysis system 
able to measure the percentage of oxy-
gen present in the mask and available 
for the patient.
Although oxygen is delivered to the 
patient in pure 100% form, there are 
always minimum leakages in the con-
tact between the mask and the face of 
the patient (the oxygen comes out and 
the ambient air enters) with a real per-
centage of oxygen in the mask reduced 
to an average of 95%. Below this per-
centage signals are activated, alerting 
the personnel within the chamber to 
check the current situation (mask not 
positioned, uncooperative patient, etc.) 
This monitoring takes place in real 
time and with each patient’s control 
step every 3–4 minutes.
Data analysis
The sEMG signals were visually in-
spected in order to select the best chan-
nels to use for variable estimates. The 
muscle fibre conduction velocity (CV) 
of the sEMG signals were computed 
off-line among all the selected chan-
nels using numerical algorithms (18) 
and non-overlapping signal epochs of 
0.5 seconds. CV was computed as e/d, 
where e is the inter-electrode distance 
and d the delay between the signals 
obtained from the two double differen-
tial arrays positioned 5 mm apart (the 
value of d was obtained by identifying 
the time-shift required to minimise the 
mean square error between the Fourier 
transforms of the two double differen-
tial signals). The correlation coefficient 
between the two adjacent double dif-
ferential signals was calculated and, if 
it was less than 0.8, the recorded sig-
nals were excluded from the analysis.  
The fractal dimension (FD) was calcu-
lated using the box-counting method 
(19) (20). The mean power spectral fre-
quency (MNF) and FD estimates were 
computed using non-overlapping signal 
epochs of 0.5 seconds and were aver-
aged among all of the accepted channels. 
The data were analysed using custom-
written software in MATLAB R2014a 
(Mathworks, Natick, MA, USA).
The maximum torque of each MVC 
was determined, and the instant at 
which it occurred was used to calculate 
the EMG variables. In the case of fa-
tiguing contractions, it has been dem-
onstrated that linear regression is the 
best model for fitting EMG data during 
sub-maximal isometric contractions 
(21), and so linear regressions were 
used to calculate the rate of change in 
the EMG variables (calculated as the 
percentage ratio between the change in 
the EMG estimate in one second and 
the initial value, and expressed as %/s).
Neuromuscolar efficency (NME) was 
calculated as the ratio between force 
and muscle fibre CV (22).
Statistical analysis
The Kolmogorov-Smirnov test was 
used to assess the normality of data 
distribution and, if the data were not 
normally distributed, they were log-
transformed before statistical analysis 
and back-transformed to obtain de-
scriptive statistics. Student’s t-tests 
for independent samples were used to 
compare maximal force and the EMG 
values at T0 vs. T1 (acute effects) and 
pre- vs. post HBOT treatment (cumu-
lative effects). The statistical analyses 
were made using SPSS statistics soft-
ware (version 20.0, IBM Corporation, 
Somers, NY, USA), and a p-value of 
<0.05 was considered statistically sig-
nificant. The data are all expressed as 
mean values ± SD.
Results
EMG results (acute effects: T0-T1)
An evaluation was made before and 
immediately after the first session. 
Maximal strength did not change af-
ter one session of HBOT (T0 49±20 
N, T1 49±19 N; p=0.792), thus sug-
gesting that it did not induce muscle 
fatigue or potentiation. There was also 
no change in conduction velocity (CV: 
T0 3.97±0.97 m/sec, T1 4.13±0.45 m/
sec; p=0.4557) or neuromuscular effi-
ciency (NME: T0 1.4±0.6, T1 1.3±0.8; 
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p=0.695), but average rectified value 
(ARV) decreased from 77±48 μV to 
72±51 μV (p=0.024). 
EMG results pre- vs. post-MCV 
(cumulative effects: T1-T20)
The mechanical and EMG variables 
recorded during the MVC are shown 
in Figure 1. There was no difference 
in maximal strength, EMG amplitude 
or muscle fibre CV before and after 
the intervention (p>0.3), but NME 
(i.e. the ratio between EMG amplitude 
and force) increased from 1.6±1.1 to 
2.1±0.8 (p=0.050).
The rate of change in the EMG varia-
bles (used as indices of the myoelectric 
manifestation of fatigue) are shown in 
Figure 2. None of these variables were 
affected by the intervention (p>0.3).
Discussion
FM is a major cause of chronic wide-
spread pain, and its general population 
prevalence of 2.3% makes it a consid-
erable burden on National Health Ser-
vices because of the delays in making 
a correct diagnosis (23) and very late 
referrals for rehabilitation. The most 
disabling aspects of the syndrome are 
pain and fatigue, but there may also be 
various combinations of other symp-
toms, the most frequent of which are 
non-refreshing sleep, mood disturbanc-
es, cognitive impairment, and a sense 
of memory loss. All of these symptoms 
and signs are related to region-specific 
anatomical changes in grey matter 
volume, central sensitisation with de-
creased functional connectivity in the 
descending pain-modulating system, 
and increased activity in the so-called 
pain matrix (24). It is therefore a com-
plex and heterogeneous clinical condi-
tion that always reduced the patients’ 
quality of life and leads to increasing 
physical, functional and emotional dis-
ability. 
Its complexity is also reflected in the 
substantial lack of efficacious phar-
macological and non-pharmacological 
treatments, whether they are used alone 
or in combination (6, 23). A wide range 
of non-pharmacological treatments 
have been tried, including various 
types of exercise, cognitive-behav-
ioural therapy, physiotherapy, physical 
therapy including transcutaneous elec-
trical nerve stimulation, LASER treat-
ment of trigger points, heat and cold, 
balneotherapy and acupuncture (7, 25).
HBOT has also been suggested because, 
under normal circumstances, oxygen is 
transported throughout the body only by 
red blood cells, whereas HBOT allows 
oxygen to be carried into all body fluids, 
plasma, lymph, bone and central nerv-
ous system fluids, and areas where blood 
circulation is diminished or blocked 
(26). In vitro, HBOT increases cell me-
tabolism, reduces apoptosis, alleviates 
oxidative stress, and increases neurotro-
phin and nitric oxide levels by enhanc-
ing mitochondrial function in neurons 
and glial cells, and it may even promote 
the neurogenesis of endogenous neural 
stem cells (27, 28).
On the basis of these premises and MNF 
findings of altered cortical activity in 
FM patients, two Israeli groups (10-12) 
have evaluated the efficacy of HBOT 
in improving fibromyalgia symptoms 
by rectifying the typically altered brain 
functions. Both groups suggest that the 
clinical improvement is due to a pri-
mary improvement in central functions 
that is only secondarily reflected on 
muscle fatigue and pain.
The aim of this study was to look direct-
ly at muscle in order to assess whether 
the rearranged cortical activity induced 
by HBOT can really improve neuromus-
cular efficiency and therefore muscle 
function. To this end, sEMG was used 
as a widely accepted and reproducible 
means of evaluating muscle fatigue be-
cause its variables correlate with acute 
alterations in motor unit recruitment 
strategies and/or chronic changes in the 
number or size of muscle fibre types that 
reflect muscle biopsy findings and can 
be used to foresee the mechanical and 
functional impairments observed in bio-
mechanical and clinical studies, includ-
ing neuromuscular efficiency and the 
early development of fatigue (18, 22).
We have previously used sEMG to ob-
serve altered neuromuscular efficiency 
in FM patients (5), whose muscles 
simply work inefficiently rather than 
showing any specific alteration capable 
of explaining pain and muscle fatigue, 
and these seems to be related to a fail-
ure in central control due to an altera-
tion in suprasegmental control. These 
conclusions are supported by the find-
Fig. 1. Mean mechanical and electromyographical (EMG) values recorded during MVC (Maximum Voluntary Contractor); average rectified EMG ampli-
tude; NME (i.e. the ratio between force and ARV); and muscle fibre CV. *p=0.050. 
Fig. 2. Mean (SD) rate of change in EMG variables during the fatiguing contraction (30 seconds at 60% of 
maximal force): muscle fibre CV; mean power spectra frequency of the EMG signal (MNF); fractal dimen-
sion of the EMG signal (FD). There were not statistically significant differences between PRE vs. POST.
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ings of the present study showing the 
same sEMG picture in the pre- HBOT 
tests: i.e. patients with FM are affect-
ed by neuromuscular inefficiency that 
is mainly due to altered central motor 
drive. As there were no changes in mus-
cle fibres, these findings suggest that 
HBOT acted at central level by induc-
ing a change in adopted strategies, op-
timising mechanical output, and reduc-
ing the myoelectrical manifestations of 
fatigue. This possibility has previously 
been demonstrated in healthy subjects 
using a different conditioning treatment 
(29-31). 
In terms of the acute effects of HBOT 
on sEMG parameters, evaluations were 
made before and immediately after 
the first session showing that maximal 
strength had not changed (T0 49±20 N, 
T1 49±19 N, p=0.792), thus suggest-
ing that HBOT did not induce muscle 
fatigue or potentiation. However, after 
20 sessions of HBOT, neuromuscular 
efficiency (i.e. the ratio between EMG 
amplitude and force) increased from 
1.6±1.1 to 2.1±0.8 (p=0.050), whereas 
maximal strength, EMG amplitude and 
muscle fibre CV did not change. 
In other words, HBOT did not improve 
muscle strength or change muscle fibre 
content, but improved the ability of the 
central motor command to generate 
the same effort (MVC) with fewer re-
cruited fibres. Our sEMG findings un-
derlined a modified central mechanism 
related to fibre type recruitment order, 
thus suggesting that muscle fatigue is 
not primarily a muscular problem, as 
also demonstrated by other authors with 
different methods.
This study has some limitations:  it was 
not a double-blind RCT, and it used dif-
ferent HBOT parameters from those 
used by the Israeli groups. However, 
a double-blind RCT did not seem to 
be practical because of the high risk of 
dropouts due the length of the treatment 
(20 sessions of approximately 90 min-
utes). Moreover, all of the enrolled pa-
tients were in controlled rehabilitation 
and had undergone a long list of previ-
ous physical therapies: the introduction 
of another control would have led to a 
substantial bias.
In relation to the HBOT parameters 
used, there was a general agreement 
among the authors that a treatment du-
ration of 40 sessions was not realistic in 
our local situation because the patients 
attending the recruiting centre came 
from all over Italy. We therefore de-
cided to reduce the number of sessions 
from 40 to 20, and to increase chamber 
pressure to 2.4 atm instead of using the 
2 atm used in the other experiments. 
We are aware that the statistical signifi-
cance of the improvement in NME ob-
served in our study may have been due 
to the reduction in the number of ses-
sions, which raises the question of the 
right HBOT dose for FM. This is funda-
mentally important not only because the 
length of the treatment may be difficult 
for the patients to cope with, but also 
(and more importantly) because HBOT 
is a recognised pharmacological treat-
ment (30) and the appropriate dose has 
to be carefully assessed. There is there-
fore a need to develop HBOT protocols 
and establish the intensity (O2 atm) and 
duration and number of individual ses-
sions for patients with this specific pa-
thology, all of which will require more 
research and a shared consensus con-
cerning the best treatment/dose. 
Acknowledgements
We are very grateful to all the staff of 
the HBOT Service of Habilita, Hospi-
tals & Research, Zingonia: they are so 
many that it is not possible to mention 
them all. Our special thanks to Ugo Pani 
MD, HBOT medical manager, to Rob-
erto Scandella, engineer, HBOT techni-
cal supervisor and our neurophysiopa-
thology technicians, Marzia Calabrese 
and Gianpiero Buttacchio, who did all 
of the sEMG recordings.
References 
  1. CABO-MESEGUER A, CERDÁ-OLMEDO G, 
TRILLO-MATA JL: Fibromialgia: preva-
lencia, perfiles epidemiológicos y costes 
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